Atriva Therapeutics GmbH
3 clinical trials · Sponsor
◉ Watch Atriva Therapeutics GmbH
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib (NCT05555823) | Atriva Therapeutics GmbH | 2022-06-23 |
| Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19 (NCT04776044) | Atriva Therapeutics GmbH | 2021-04-12 |
| Phase 1 Study of ATR-002 (NCT04385420) | Atriva Therapeutics GmbH | 2019-04-24 |
Track Atriva Therapeutics GmbH automatically
Every clearance here is in the API, with alerts when new ones post.